Intrinsiqq
Formycon AG logo

Formycon AG Financials

FYB.XETR

⊜ Compare

All currency values in € millions unless otherwise noted

Scroll

Income Statement
DEC 2025
DEC 2024
DEC 2023
DEC 2022
DEC 2021
Revenues
Revenue€44€70€78€42€37
Cost of Revenue€41€55€54€30€27
Gross Profit€4€15€23€12€10
Total Operating Expenses€34€38€24€30€24
Operating Income-€31-€24-€0-€18-€14
Non-Operating
Net Interest Expense-€3-€1-€0-€0-€0
Income Tax Expense-€26-€19€3€1-€1
Net Income
Net Income-€65-€126€76€36-€13
Per Share Data
Revenue Per Share€2.54€3.98€4.88€3.10€3.32
EPS (Basic)-€3.70-€7.18€4.76€2.62-€1.20
EPS (Diluted)-€3.70-€7.18€4.72€2.59-€1.20
Shares Outstanding17.5M17.5M15.9M13.7M11.0M

Formycon (FYB.XETR) financials: revenue, profit and margins

Formycon (FYB.XETR) generated about €44 million in revenue and -€65 million in net income (a -145.5% net margin) over the trailing twelve months, growing at roughly 5.0% a year. Figures are from company filings; this is analysis, not investment advice.

Frequently asked

What is Formycon's (FYB.XETR) revenue?+

Formycon generated about €44 million in revenue over the trailing twelve months. Revenue has grown at roughly 5.0% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.

Is Formycon profitable?+

Formycon reported about -€65 million in net loss over the trailing twelve months, a net margin of roughly -145.5%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

What are Formycon's profit margins?+

Formycon runs a gross margin of about 8.0%, an operating margin of about -68.6%, a net margin of about -145.5%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.

How fast is Formycon growing?+

Formycon's revenue has compounded at roughly 5.0% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside FYB.XETR's margins and free cash flow. This is analysis from company filings, not investment advice.

How the market compares: How many US companies are profitable

Peers

Biotechnology · Pick stocks to compare with FYB.XETR

CompareIntrinsic value
LIK.XETRLimes Schlosskliniken AG
€530.00+1.92%67
7V0.XETRDarwin AG
€6.30-3.08%24
AJ91.XETRDocCheck AG
€10.50+0.00%57
M3V.XETRMeVis Medical Solutions AG
€19.90-0.50%48
GME.XETRGeratherm Medical AG
€2.13+0.00%47
AAQ1.XETRaap Implantate AG
€1.47+1.38%33
HPHA.XETRHeidelberg Pharma AG
€2.01-3.37%10
BIG1.XETRBio-Gate AG
€2.38+2.59%36

Spot a number that looks wrong?

Download this analysis as a PDF (Pro)

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing FYB.XETR

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.